மரம் மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001 Timber PharmaceuticalsApril 28, 2021 GMT - Company is evaluating a topical pharmaceutical composition of isotretinoin for the treatment of moderate to severe subtypes of congenital ichthyosis - Basking Ridge, NJ, April 28, 2021 (GLOBE NEWSWIRE) via NewMediaWire   Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the Japanese Patent Office has decided to grant a patent (No. 2018-542677) for its lead asset, TMB-001, the Company’s topical pharmaceutical composition of isotretinoin that is currently being evaluated for the treatment of moderate to severe subtypes of congenital ichthyosis (CI).

United statesAdam daleyJohn koconisExchange commissionNewmediawire timber pharmaceuticals incCompany annual report on formBerry company public relationsSecurities exchangeTimber pharmaceuticals incJapanese patent officeChief executive officerOrphan products clinical trials grantTimber pharmaceuticalsSecurities actSecurities exchange actPrivate securities litigation reform act